 Glucagon
"Glucagon" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511)
| Descriptor ID |
D005934
|
| MeSH Number(s) |
D06.472.699.587.469.500 D12.644.548.586.469.500
|
| Concept/Terms |
Glucagon- Glucagon
- Proglucagon (33-61)
- HG-Factor
- HG Factor
- Hyperglycemic-Glycogenolytic Factor
- Hyperglycemic Glycogenolytic Factor
- Glucagon (1-29)
- Glukagon
|
Below are MeSH descriptors whose meaning is more general than "Glucagon".
Below are MeSH descriptors whose meaning is more specific than "Glucagon".
This graph shows the total number of publications written about "Glucagon" by people in this website by year, and whether "Glucagon" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 2 | 2 | | 2000 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 4 | 4 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 4 | 4 | | 2009 | 0 | 4 | 4 | | 2011 | 1 | 2 | 3 | | 2012 | 0 | 2 | 2 | | 2013 | 2 | 0 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 2 | 0 | 2 | | 2016 | 3 | 1 | 4 | | 2017 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 2 | 0 | 2 | | 2021 | 1 | 2 | 3 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 2 | 0 | 2 | | 2025 | 2 | 0 | 2 | | 2026 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon" by people in Profiles.
-
Tanner AR, Cilvik SN, Nguyen MA, Brown LD, Anthony RV, Wright CJ, Wesolowski SR, Rozance PJ. Experimental chronic fetal hyperglucagonemia stimulates hepatic pathways for amino acid catabolism and gluconeogenesis. J Endocrinol. 2026 Apr 01; 269(1).
-
Zhu W, Pan L, Cui X, Russo AC, Ray R, Pederson B, Wei X, Lin LL, Torres M, Hafner H, Gregg B, Shrestha N, Liu C, Naji A, Arvan P, Sandoval DA, Lindberg I, Qi L, Reinert RB. SEL1L-HRD1 ER-associated degradation facilitates prohormone convertase 2 maturation and glucagon production in islet a cells. Nat Commun. 2026 Feb 25; 17(1).
-
Kahn SE, Tripputi M, Lachin JM, Balasubramanyam A, Banerji MA, Barzilay J, Cohen RM, Garvey WT, Gramzinski MR, Rasouli N, Rhee M, Seegmiller JC, Singh V, Sivitz WI, Steffes MW, Utzschneider K, DeFronzo RA. Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2026 Feb 01; 49(2):325-334.
-
Mason E, Karakus KE, Akturk HK. Barriers to glucagon use in patients with type 1 diabetes. Prim Care Diabetes. 2025 Jun; 19(3):341-343.
-
Tanner AR, Cilvik SN, Nguyen MA, Dobrinskikh E, Anthony RV, Wesolowski SR, Rozance PJ. A Two-Hour Fetal Glucagon Infusion Stimulates Hepatic Catabolism of Amino Acids in Fetal Sheep. Int J Mol Sci. 2025 Feb 22; 26(5).
-
Cilvik SN, Boehmer B, Wesolowski SR, Brown LD, Rozance PJ. Chronic late gestation fetal hyperglucagonaemia results in lower insulin secretion, pancreatic mass, islet area and beta- and a-cell proliferation. J Physiol. 2024 11; 602(22):6329-6345.
-
Lawler HM, Patti ME, Krecic MR, Rowell J, Dobs A, Nguyen A, Conoscenti V. Mini-Dose Ready-to-Use Liquid Glucagon for Post-Bariatric Hypoglycemia Treatment in Experimental and Real-World Settings. Obes Surg. 2024 10; 34(10):3897-3900.
-
Finn E, Severn C, Pyle L, Garrish J, Vigers T, Behn CGD, Zeitler PS, Sagel SD, Nadeau KJ, Chan CL. Hypoglycemia in children and young adults with cystic fibrosis during oral glucose tolerance testing vs. continuous glucose monitoring. Pediatr Pulmonol. 2023 09; 58(9):2495-2504.
-
Lynch CS, Kennedy VC, Tanner AR, Ali A, Winger QA, Rozance PJ, Anthony RV. Impact of Placental SLC2A3 Deficiency during the First-Half of Gestation. Int J Mol Sci. 2022 Oct 19; 23(20).
-
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 10; 28(10):2092-2099.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|